Get startedLog in
    Picture of Ventyx Biosciences logo

    VTYX — Ventyx Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapHigh Flyer
    All News

    Brief: Ventyx Biosciences Announces Initiation Of Dosing In A Phase 2A Trial Of Vtx3232 In Patients With Early Parkinson’S Disease

    Picture of Ventyx Biosciences logoVentyx Biosciences
    06/09/2024 14:02
    Ventyx Biosciences Inc  VTYX.O :
    * VENTYX BIOSCIENCES ANNOUNCES INITIATION OF DOSING IN A
PHASE 2A
TRIAL OF VTX3232 IN PATIENTS WITH EARLY PARKINSON’S DISEASE
    * VENTYX BIOSCIENCES INC: EXPECT TO REPORT TOPLINE RESULTS
FROM
THIS TRIAL IN 2025.

Source text for Eikon:  ID:nGNX3NWVPd 
Further company coverage:  VTYX.O

    Recent news on Ventyx Biosciences

    See all news